168 related articles for article (PubMed ID: 37324948)
1. Synergism of FAK and ROS1 inhibitors in the treatment of
Gao J; Yao Y; Liu C; Xie X; Li D; Liu P; Wang Z; Zhang B; Ren R
Int J Biol Sci; 2023; 19(9):2711-2724. PubMed ID: 37324948
[No Abstract] [Full Text] [Related]
2. E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Bajrami I; Marlow R; van de Ven M; Brough R; Pemberton HN; Frankum J; Song F; Rafiq R; Konde A; Krastev DB; Menon M; Campbell J; Gulati A; Kumar R; Pettitt SJ; Gurden MD; Cardenosa ML; Chong I; Gazinska P; Wallberg F; Sawyer EJ; Martin LA; Dowsett M; Linardopoulos S; Natrajan R; Ryan CJ; Derksen PWB; Jonkers J; Tutt ANJ; Ashworth A; Lord CJ
Cancer Discov; 2018 Apr; 8(4):498-515. PubMed ID: 29610289
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Chen I; Mathews-Greiner L; Li D; Abisoye-Ogunniyan A; Ray S; Bian Y; Shukla V; Zhang X; Guha R; Thomas C; Gryder B; Zacharia A; Beane JD; Ravichandran S; Ferrer M; Rudloff U
J Transl Med; 2017 May; 15(1):92. PubMed ID: 28460635
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.
Tan X; Kong D; Tao Z; Cheng F; Zhang B; Wang Z; Mei Q; Chen C; Wu K
Biomark Res; 2024 Jan; 12(1):13. PubMed ID: 38273343
[TBL] [Abstract][Full Text] [Related]
5. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
Sun R; Meng Y; Xu R; Li Y; Xu X; Li Z; Zuo D
Cell Signal; 2023 Jan; 101():110497. PubMed ID: 36265718
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-Function
Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
Godwin TD; Kelly ST; Brew TP; Bougen-Zhukov NM; Single AB; Chen A; Stylianou CE; Harris LD; Currie SK; Telford BJ; Beetham HG; Evans GB; Black MA; Guilford PJ
Gastric Cancer; 2019 Mar; 22(2):273-286. PubMed ID: 30066183
[TBL] [Abstract][Full Text] [Related]
9. Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
Li J; Lan M; Peng J; Xiong Q; Xu Y; Yang Y; Zhou Y; Liu J; Zeng Z; Yang X; Zhang Z; Zhang P; Zhu Q; Wu W
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627188
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
11. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
12. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
[TBL] [Abstract][Full Text] [Related]
13. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.
Ogura H; Nagatake-Kobayashi Y; Adachi J; Tomonaga T; Fujita N; Katayama R
Sci Rep; 2017 Jul; 7(1):5519. PubMed ID: 28717217
[TBL] [Abstract][Full Text] [Related]
14. EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis.
Shih CH; Chang YJ; Huang WC; Jang TH; Kung HJ; Wang WC; Yang MH; Lin MC; Huang SF; Chou SW; Chang E; Chiu H; Shieh TY; Chen YJ; Wang LH; Chen L
Oncogene; 2017 Nov; 36(47):6542-6554. PubMed ID: 28759046
[TBL] [Abstract][Full Text] [Related]
15. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
[TBL] [Abstract][Full Text] [Related]
16. ROS1-dependent cancers - biology, diagnostics and therapeutics.
Drilon A; Jenkins C; Iyer S; Schoenfeld A; Keddy C; Davare MA
Nat Rev Clin Oncol; 2021 Jan; 18(1):35-55. PubMed ID: 32760015
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and cancer risk in families with pathogenic
Xicola RM; Li S; Rodriguez N; Reinecke P; Karam R; Speare V; Black MH; LaDuca H; Llor X
J Med Genet; 2019 Dec; 56(12):838-843. PubMed ID: 31296550
[TBL] [Abstract][Full Text] [Related]
18. Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.
Peng K; Zhang F; Wang Y; Sahgal P; Li T; Zhou J; Liang X; Zhang Y; Sethi N; Liu T; Zhang H; Bass AJ
Clin Cancer Res; 2023 Jan; 29(1):197-208. PubMed ID: 36278961
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
Golubovskaya VM; Gross S; Kaur AS; Wilson RI; Xu LH; Yang XH; Cance WG
Mol Cancer Res; 2003 Aug; 1(10):755-64. PubMed ID: 12939401
[TBL] [Abstract][Full Text] [Related]
20. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
